RecruitingPhase 1NCT06638307
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer
Sponsor
Stemline Therapeutics, Inc.
Enrollment
240 participants
Start Date
Oct 25, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Participant has advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.
- Participant must have received at least one prior line of endocrine therapy for advanced/metastatic disease or participant who has radiological evidence of breast cancer recurrence or progression during or within 12 months from the end of or during adjuvant treatment with endocrine therapy, as these participants are considered as first-line relapsed participants. Progression on previous cyclin-dependent kinase 4/6 inhibitor treatment in combination with fulvestrant or aromatase inhibitor is required. No other therapeutic options are considered appropriate by the investigator.
- Up to 6 prior lines of systemic therapy (including up to 2 prior lines consisting of chemotherapy, cytotoxic antibody drug conjugate, or a combination of both regimens) are allowed in the advanced/metastatic setting.
- Presence of genetic alterations in PIK3CA/AKT1/PTEN in participants' tumor tissue.
Exclusion Criteria2
- Active or newly diagnosed central nervous system metastases.
- Participants with advanced, symptomatic visceral spread, who are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or liver involvement \>50%.
Interventions
DRUGMEN2312
MEN2312 administered as oral tablets.
DRUGElacestrant
Elacestrant administered as oral tablets.
Locations(30)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06638307
Related Trials
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892139 locations
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT066493311 location
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT0699384410 locations
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT0699702921 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT042224132 locations